A 52-year-old woman with acute myocardial infarction complicated by cardiogenic shock (cardiac index 1.8 L/min/m², PCWP 22 mmHg, SBP 78 mmHg) is on mechanical ventilation. She has received optimal fluid management and is on noradrenaline 0.1 mcg/kg/min. What is the drug of choice to improve contractility and reduce afterload in this patient?

Explanation

## Inotropic Support in Cardiogenic Shock **Key Point:** Dobutamine is the preferred inotropic agent in cardiogenic shock when systolic dysfunction and elevated filling pressures coexist, as it improves contractility while reducing afterload. ### Pathophysiology of Cardiogenic Shock in This Case The patient has: - **Low cardiac index** (1.8 L/min/m²; normal >2.2) → systolic dysfunction - **Elevated PCWP** (22 mmHg; normal <18) → pulmonary congestion - **Hypotension** (SBP 78 mmHg) → inadequate perfusion pressure This requires an agent that: 1. Increases contractility (inotrope) 2. Reduces systemic vascular resistance (vasodilator) 3. Improves coronary perfusion pressure ### Inotropic Agents in Cardiogenic Shock | Agent | Inotrope | Vasodilator | SVR | HR | Arrhythmia Risk | Use | | --- | --- | --- | --- | --- | --- | --- | | **Dobutamine** | +++ | +++ | ↓ | ↑↑ | Moderate | **First-line for low CO + ↑ PCWP** | | Milrinone | ++ | +++ | ↓↓ | ↑ | Low | Hypotensive patients; adjunct | | Levosimendan | +++ | +++ | ↓ | ↔ | Low | Not available in USA/India | | Epinephrine | +++ | ± | ↑ | ↑↑↑ | High | Refractory shock only | **High-Yield:** Dobutamine is a β1-agonist with β2 effects at higher doses. It increases contractility and causes peripheral vasodilation, reducing afterload — ideal for cardiogenic shock with elevated filling pressures. ### Mechanism of Dobutamine 1. **β1 effect (dominant):** Increases myocardial contractility and heart rate 2. **β2 effect (at higher doses):** Peripheral vasodilation → reduced SVR and PCWP 3. **Net result:** Improved cardiac output with reduced pulmonary congestion **Clinical Pearl:** In cardiogenic shock post-MI, dobutamine + noradrenaline combination is often used: noradrenaline maintains perfusion pressure while dobutamine improves contractility and reduces afterload. This is superior to either agent alone. ### Dosing - **Dobutamine:** 2.5–10 mcg/kg/min IV infusion, titrate to cardiac index >2.2 L/min/m² - Monitor for tachycardia and arrhythmias (common at doses >5 mcg/kg/min) - Reassess need for mechanical circulatory support (IABP, ECMO) if refractory **Warning:** Dobutamine can cause systemic hypotension at high doses due to excessive vasodilation. This patient requires concurrent noradrenaline to maintain MAP. Avoid as monotherapy in hypotensive cardiogenic shock.